Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone ...
The main market opportunities in the CLDN18.2-targeted immunotherapy space include next-gen monoclonal antibodies with enhanced efficacy, innovative antibody-drug conjugates (ADCs), advanced CAR-T and ...
UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...
Cancer prevention takes many forms: sunscreen, stress reduction, regular screenings. Only recently have scientists begun to ...
Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effective April 1, 2026.
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...
The search space for protein engineering grows exponentially with complexity. A protein of just 100 amino acids has 20100 possible variants—more combinations than atoms in the observable universe.
Mayo Clinic researchers and collaborators have identified a previously unrecognized way lung tumors weaken the immune system, helping explain why many patients do not respond to immunotherapy and ...
Wondering why the same virus hits you worse A recent study reveals the influence of age and sex on our immune response Read ahead to find out ...
The framework predicts how proteins will function with several interacting mutations and finds combinations that work well together.
This is an important study that identifies the developmental time window during which re-expression of TCF4 mutated in Pitt-Hopkins syndrome, can rescue phenotypic features of brain function in a TCF4 ...
Most people have the Epstein-Barr (EBV) virus. Sometimes people are unaware of this virus in their body; it settles into immune cells and remains for the duration. Although EBV does not cause illness ...